Lung transplant and cystic fibrosis: What's new from the UK and France?

Thorax

Volumn 63, Issue 8, 2008, Pages 668-670

  Noone, Peadar G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BURKHOLDERIA CEPACIA; CARDIOPULMONARY BYPASS; CYSTIC FIBROSIS; EDITORIAL; FRANCE; GRAFT FAILURE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART LUNG TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LUNG PERFUSION; LUNG TRANSPLANTATION; MEDICAL SPECIALIST; ORGAN DONOR; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED KINGDOM;

EID: 49149115664     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2008.099622     Document Type: Editorial

References (15)

1. CFF. 2007. Cystic Fibrosis Foundation Patient Registry. 2006 Annual Report to the Center Directors. Bethesda: CFF, 2006.
2. Liou TG, Adler FR, Cox DR, et al. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007;357:2143-52.
3. Sweet SC, Aurora P, Benden C, et al. Lung transplantation and survival in children with cystic fibrosis: solid statistics - flawed interpretation. Pediatr Transplant 2008;12:129-36.
4. Egan TM. Solid benefit of lung transplantation for some children with cystic fibrosis. Pediatr Transplant 2008;12:125-8.
5. Aurora P, Spencer H, Moreno-Galdo A. Lung transplantation in children with cystic fibrosis. A view from Europe. Am J Respir Crit Care Med 2008;177:935-6.
6. Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008;63:725-31.
7. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008;63:732-7.
8. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria: I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-34.
9. Jordan PW, Stanley T, Donnelly FM, et al. Atypical mycobacterial infection in patients with cystic fibrosis: update on clinical microbiology methods. Lett Appl Microbiol 2007;44:459-66.
10. Ailawadi G, Smith PW, Oka T, et al. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008;135:594-602.
11. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001;358:1780-1.
12. Aris RM, Routh JC, Lipuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-6.
13. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001;163:43-8.
14. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008;8:1025-30.
15. Egan TM, Detterbeck FC, Mill M, et al. Impact of Burkholderia species on outcome of lung transplantation for CF patients. Pediatr Pulmonol 2005;28(Suppl):365.